Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
CLEO Diagnostics Ltd ( (AU:COV) ) has shared an announcement.
Cleo Diagnostics Ltd responded to an ASX price query regarding the recent increase in its share price, highlighting its high-performing Ovarian Cancer detection technology currently in clinical trials for FDA approval. The announcement coincides with the start of Ovarian Cancer Awareness Month, emphasizing the company’s unique position as the sole ASX-listed entity focused on this critical women’s health issue.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is a medical technology company listed on the ASX, specializing in the development of a blood test for the early diagnosis of Ovarian Cancer. The company focuses on creating simple and accurate diagnostic solutions and is actively engaged in clinical trials in the U.S. to secure FDA approval.
YTD Price Performance: 1.39%
Average Trading Volume: 56,330
Technical Sentiment Consensus Rating: Strong Sell
See more insights into COV stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue